title: ESR1 Mutations Prevalent in Some Breast Cancers.
abstract: A recent analysis of cell-free DNA from blood samples found that ESR1 mutations are highly prevalent and associated with worse overall survival in women with advanced estrogen receptor-positive breast cancer that progressed on aromatase inhibitor therapy. The data also show that patients' mutation status may affect their response to the mTOR inhibitor everolimus.
mesh_terms: D000730:Androstadienes / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000235:genetics; D017326:Clinical Trials, Phase III as Topic; D003226:Congresses as Topic; D047628:Estrogen Receptor alpha / Q000097:blood / Q000235:genetics*; D000068338:Everolimus / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009154:Mutation; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha; D000068338:Everolimus; C056516:exemestane